Susceptibility trending of blood isolates of the Bacteroides fragilis group over a 12-year period to clindamycin, ampicillin-sulbactam, cefoxitin, imipenem, and metronidazole

Anaerobe

Volumn 8, Issue 6, 2002, Pages 301-305

  Aldridge, Kenneth E ^a   Sanders, Charles V ^a  

^a LA Stt Univ Health Sciences Center ^*  (United States)

Author keywords

Antimicrobial susceptibility; Bacteroides fragilis group; Blood isolates; Species ratios

Indexed keywords

ANTIINFECTIVE AGENT; CEFOXITIN; CLINDAMYCIN; IMIPENEM; METRONIDAZOLE; SULTAMICILLIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; BLOOD ANALYSIS; BLOOD SAMPLING; COMPARATIVE STUDY; CONFERENCE PAPER; DILUTION; DRUG ACTIVITY; DRUG SCREENING; DRUG SENSITIVITY; NONHUMAN; PRIORITY JOURNAL; RATING SCALE;

BACTEROIDES; BACTEROIDES FRAGILIS;

EID: 0036987461     PISSN: 10759964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1075-9964(03)00028-3     Document Type: Conference Paper

References (19)

1. Redondo M.C., Arbo M.D.J., Grindlinger J., Snydman D.R. Attributable mortality of bacteremia associated with the Bacteroides fragilis group. Clin Infect Dis. 20:1995;1492-1496.
2. Nguyen M.H., Yu V.L., Morris A.J., McDermott L., Wagener M.W., Harrell L., Snydman D.R. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia. findings of a multicenter prospective observational trial Clin Infect Dis. 30:2000;870-876.
3. Finegold S.M. The National Committee for Clinical Laboratory Standards Working Group on Anaerobic Susceptibility Testing. Susceptibility testing of anaerobic bacteria J Clin Microbiol. 26:1988;1253-1256.
4. Holdeman L.V., Cato E.P., Moore W.E.C. Anaerobe laboratory manual. 4th ed. 1977;Virginia Polytechnic Institute and State University, Blacksburg, VA.
5. Summanen P., Baron E.J., Citron D., Strong C., Wexler H.M., Finegold S.M. Wadsworth anaerobic bacteriology manual. 5th ed. 1993;Star Publishing Company, Belmont, CA.
6. National Committee for Clinical Laboratory Standards. Approved Standard M11-A4. Methods for antimicrobial susceptibility testing of anaerobic bacteria. National Committee for Clinical Laboratory Standards, Villanova, PA, 1997.
7. Hentges D.J. Anaerobes as normal flora. Finegold S.M., George W.L. Anaerobic infections in humans. 1989;37-53 Academic Press, San Diego, CA.
8. Tally F.P., Cuchural G.J., Jacobus N.V., Gorbach S.L., Aldridge K.E., Cleary T.J., Finegold S.M., Hill G.B., Iannini P.B., McCloskey R.V., O'Keefe J.P., Pierson C.L. Susceptibility of the Bacteroides fragilis group in the United States in 1981. Antimicrob Agents Chemother. 23:1983;536-540.
9. Tally F.P., Cuchural G.J. Jr., Jacobus N.V., Gorbach S.L., Aldridge K., Cleary T., Finegold S.M., Hill G., Iannini P., O'Keefe J.P., Pierson C. Nationwide study of the Bacteroides fragilis group in the United States. Antimicrob Agents Chemother. 28:1985;675-677.
10. Cuchural G.J. Jr., Tally F.P., Jacobus N.V., Gorbach S.L., Aldridge K., Cleary T., Finegold S.M., Hill G., Iannini P., O'Keefe J.P., Pierson C. Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States. comparison of 1981 and 1982 Antimicrob Agents Chemother. 26:1984;145-148.
11. Cuchural G.J. Jr., Tally F.P., Jacobus N.V., Aldridge K., Cleary T., Finegold S.M., Hill G., Iannini P., O'Keefe J.P., Pierson C., Crook D., Russo T., Hecht D. Susceptibility of the Bacteroides fragilis group in the United States. analysis by site of infection Antimicrob Agents Chemother. 32:1988;717-722.
12. Aldridge K.E., Gelfand M., Reller L.B., Ayers L.W., Pierson C.L., Schoenknect F., Tilton R.C., Wilkins J., Henderberg A., Schiro D.D., Johnson M., Janney A., Sanders C.V. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamycins, penicillins, clindamycin, and metronidazole in the United States. Diagn Microbiol Infect Dis. 18:1994;235-241.
13. Aldridge K.E., Ashcraft D., Cambre K., Pierson C.L., Jenkins S.G., Rosenblatt J.E. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother. 45:2001;1238-1343.
14. Golan Y, Jacobus NV, McDermott LA, Supran S, Hecht DW, Goldstein E, Venezia R, Harrell L, Jenkins S, Rihs J, Pierson C, Gorbach SL, Finegold S, Snydman DR. The changing epidemiology of Bacteroides species infections in the US. Presented at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. [Abstr. 1209].
15. Oteo J., Aracil B., Alós J.I., Gómez-Garcës J.L. High prevalence of resistance to clindamycin in Bacteroides fragilis group isolates. J Antimicrob Chemother. 45:2000;691-693.
16. Aldridge K.E. In vitro susceptibility of Bacteroides fragilis group strains from abscesses, body fluids, and wound/tissue sources. Drug Invest. 4(Suppl. 1):1992;1-6.
17. Brook I. Recovery of anaerobic bacteria from clinical specimens in 12 years at two military hospitals. J Clin Microbiol. 26:1988;1181-1188.
18. Patey O., Varon E., Prazuck T., Podglajen I., Dublanchet A., Dubreuil L., Breuil J. Multicentre survey in France of the antimicrobial susceptibilities of 416 blood culture isolates of the Bacteroides fragilis group. J Antimicrob Chemother. 33:1994;1029-1034.
19. Montravers P., Gauzit R., Muller C., Marmuse J.P., Fichelle A., Desmonts J.M. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis. 23:1996;486-494.